Rogaczewski Patryk, Janiak Michał, Borowczak Jędrzej, Szylberg Łukasz
Department of Tumor Pathology and Pathomorphology, Oncology Centre in Bydgoszcz ul. Romanowska, Prof. Franciszek Łukaszczyk Memorial Hospital, 85-796, Bydgoszcz, Poland.
Department of Obstetrics, Gynaecology and Oncology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.
Clin Transl Oncol. 2025 Apr;27(4):1558-1568. doi: 10.1007/s12094-024-03695-y. Epub 2024 Sep 5.
Triple-negative breast cancer (TNBC) is one of the most aggressive cancers in women, therefore it is necessary to determine novel prognostic markers to estimate survival and advancement the treatment of the disease. Recently, PCMT1, a protein mediating TNBC immune infiltration, has gained attention as a potential therapeutic target. The aim of the study was to demonstrate the relationship between PCMT1 protein overexpression as a prognostic indicator for patients with TNBC cancer and patient survival.
The study included 64 samples collected from 64 TNBC patients. We used the ImageJ software with the IHC Profiler driver for image analysis. To improve the reliability of the results, we expanded the analysis by including The Cancer Genome Atlas cohort.
We observed strong PCMT1 immunoreactivity in breast cancer samples and PCMT1 expression in TNBC was significantly higher than in the control group. Patients with high PCMT1 expression had a significantly lower overall survival rate (60.62% vs. 90.35%, respectively) than patients with low PCMT1 expression. In our study and TCGA groups, PCMT1 expression did not correlate with lymph node involvement and distant metastases but correlated with tumor stage. The results obtained in a larger TCGA group are consistent with those in our research group. Overexpression of PCMT1 was a prognostic marker of shorter survival in patients with TNBC.
The overexpression of the PCMT1 protein in triple negative breast cancer significantly correlated with shorter overall survival. The confirmed association could be a potential prognostic biomarker for patients with TNBC.
三阴性乳腺癌（TNBC）是女性中最具侵袭性的癌症之一，因此有必要确定新的预后标志物，以评估生存率并推进该疾病的治疗。最近，PCMT1作为一种介导TNBC免疫浸润的蛋白质，已成为潜在的治疗靶点而受到关注。本研究的目的是证明PCMT1蛋白过表达作为TNBC患者的预后指标与患者生存率之间的关系。
本研究纳入了从64例TNBC患者中收集的64个样本。我们使用带有免疫组化分析器驱动程序的ImageJ软件进行图像分析。为提高结果的可靠性，我们纳入了癌症基因组图谱队列来扩展分析。
我们在乳腺癌样本中观察到强烈的PCMT1免疫反应性，TNBC中PCMT1的表达明显高于对照组。PCMT1高表达患者的总生存率（分别为60.62%和90.35%）明显低于PCMT1低表达患者。在我们的研究组和TCGA组中，PCMT1表达与淋巴结受累和远处转移无关，但与肿瘤分期相关。在更大的TCGA组中获得的结果与我们研究组的结果一致。PCMT1过表达是TNBC患者生存时间较短的预后标志物。
PCMT1蛋白在三阴性乳腺癌中的过表达与较短的总生存期显著相关。这一已证实的关联可能是TNBC患者潜在的预后生物标志物。
